BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 15, 2005--Sonus Pharmaceuticals, Inc. (NASDAQ:SNUS) today presented encouraging preclinical data on its novel camptothecin-based product candidate, SN2310 Emulsion, at the AACR-NCI-EORTC cancer conference. Based on animal models, administration of an emulsion containing SN2310, a new camptothecin derivative, demonstrated improved anti-tumor activity when compared to irinotecan. In addition, these studies suggest that this formulation of SN2310 may allow less frequent dosing than irinotecan, while maintaining the therapeutic effect.
